Observations
  • Millionaire
Estimated Net Worth
  • estimated net worth
    $11.7 M - $32.3 M
Salary
  • salary
    Unknown

Financial Disclosure Details - OGE Form 278e (10/13/2021)

Positions Held Outside United States Government

#
Organization
City
Position
To
1
Palo Alto, California
Consultant
Present
2
Los Angeles, California
Member, Advisory Team
Present
3
Tucson, Arizona
Member, Board of Directors (unpaid)
Present
4
Rochester, Minnesota
Member, Scientific Advisory Committee, Cardiovascular Research Center
Present
5
Cambridge, Massachusetts
Member, Nominating & Corporate Governance Committee of the Board of Directors
Present
6
Cambridge, Massachusetts
Member, Board of Directors
Present
7
Raleigh, North Carolina
Member, Board of Directors (unpaid)
Present
8
Columbus, Ohio
Member, Clinical Advisory Board (unpaid)
Present
9
Charleston, South Carolina
Member, Advisory Board, South Carolina Clinical & Translational Science Institute
Present
10
Nashville, Tennessee
Member, Biomedical Science Advisory Board, Office of Research
Present

Employment Assets & Income and Retirement Accounts

#
Description
Value
Income Type
Income Amount
1
Medical University of South Carolina
Charitable Donations Made on My Behalf
$1,000
2
Vanderbilt University Medical Center
Advisory Board Fees
$5,000
3
University of Colorado
Advisory Board Fees
$2,000
4
Centessa Pharmaceuticals, PLC
Board of Directors Fees
$20,826
5
Centessa Pharmaceuticals, PLC
Committee Fees
$563
6
Centessa Pharmaceuticals, PLC, director fees: cash receivable
$1,001 - $15,000
None (or less than $201)
7
Centessa Pharmaceuticals, PLC, committee fees: cash receivable
$1,001 - $15,000
None (or less than $201)
8
Centessa Pharmaceuticals, PLC, unvested stock options
$1,000,001 - $5,000,000
None (or less than $201)
9
Clinetic, Inc. (health software & technology solutions), vested stock options
$15,001 - $50,000
None (or less than $201)
10
Cytokinetics, Inc.
Board of Directors Fees
$41,299

Employment Agreements and Arrangements

#
Employer Or Party
City
Status And Terms
Date
1
Los Angeles, California
Pursuant to the terms of my agreement with the company, should I participate in the advisory team meeting scheduled for December 2021, I am entitled to receive unvested stock options in the company. I will forfeit my unvested stock options upon resignation.
6/2021
2
Cambridge, Massachusetts
Pursuant to my agreement with the company, I am entitled to receive any outstanding board of director’s fees and committee fees pro-rated through the date of my resignation. The company will make these payments to me in the month following the end of the quarter. Additionally, and pursuant to the terms of the companies Amended and Restated Stock Option Incentive Plan, the Administrator of the company is authorized to and has agreed to accelerate the vesting of my unvested stock options that vest prior to February 19, 2022. After February 19, 2022, my options vest on a monthly basis. Any remaining unvested options will be forfeited upon resignation. Pursuant to the terms of the plan, I have 90 days to exercise my vested options.
1/2021
3
South San Francisco, California
Pursuant to the terms of the 2004 Equity Incentive Plan & 2004 Option Agreement and the Amended & Restated 2004 Equity Incentive Plan, upon my resignation from the company I will forfeit my unvested restricted stock units and my unvested stock options. I am entitled to retain my shares of common stock and vested stock options.
2/2018
4
Raleigh, North Carolina
I currently hold vested company stock options. I will forfeit my stock options upon resignation.
10/2017
5
South San Francisco, California
I own unvested Verily Award Units. I also own Verily Employee Units, representing an equity ownership interest in the company. Under the Verily Life Sciences, LLC, Value Creation Award Plan, when the Verily Award Units vest, they are settled in Employee Units. As is consistent with the terms of the Verily Life Sciences, LLC, Value Creation Award Plan and the benefit provided to other similarly situated executives, I am permitted to cash out my vested Employee Units at any time. The value of the units is regularly set by the board. I will receive the most recent valuation. All unvested Verily Award Units will be forfeited upon my resignation from the company.
6/2017
6
Mountain View, California
I will retain the Google, LLC, 401(k) Savings Plan, a defined contribution plan. The plan sponsor will not make further contributions after my separation.
6/2017

Sources of Compensation Exceeding $5,000 in a Year

#
Source
City
Duties
1
Cambridge, Massachusetts
Member, Board of Directors; and Member, Nominating & Corporate Governance Committee of the Board of Directors
2
South San Francisco, California
Member, Board of Directors; and Member, Science & Technology Committee of the Board of Directors
3
South San Francisco, California
Senior Advisor
4
Mountain View, California
Senior Advisor (co-employment agreement with Verily Life Sciences, LLC)
5
Durham, North Carolina
Faculty Connection, LLC, arranges for lecture, discussion groups, and consulting services; I received consulting payments through Faculty Connection, LLC
6
Ridgefield, North Carolina
Lecture, discussion groups, and consulting services; received payments through Faculty Connection, LLC
7
Durham, North Carolina
Director, Duke Forge

Spouse's Employment Assets & Income and Retirement Accounts

#
Description
Value
Type
Amount
1
Spouse's IRA
1.1
Acme United Corporation (ACU)
$15,001 - $50,000
None (or less than $201)
1.2
Anika Therapeutics, Inc. (ANIK)
$15,001 - $50,000
None (or less than $201)
1.3
B&G Foods, Inc. (BGS)
$1,001 - $15,000
None (or less than $201)
1.4
Dime Community Bancshares, Inc. (DCOM)
$15,001 - $50,000
None (or less than $201)
1.5
Discovery, Inc. (DISCK)
$1,001 - $15,000
None (or less than $201)
1.6
EnerSys (ENS)
$15,001 - $50,000
None (or less than $201)
1.7
Exelixis, Inc. (EXEL)
$15,001 - $50,000
None (or less than $201)
1.8
Franchise Group, Inc. (FRG)
$15,001 - $50,000
None (or less than $201)
1.9
Greenhill & Co., Inc. (GHL)
$15,001 - $50,000
None (or less than $201)

Other Assets and Income

#
Description
Value
Type
Amount
1
U.S. bank account #1 (cash)
$15,001 - $50,000
None (or less than $201)
2
U.S. bank account #2 (cash)
$15,001 - $50,000
None (or less than $201)
3
U.S. credit union account (cash)
$15,001 - $50,000
None (or less than $201)
4
U.S. brokerage account #1
4.1
JPMorgan Ultra-Short Municipal Income ETF (JMST)
$15,001 - $50,000
$201 - $1,000
4.2
Applied Finance Explorer Fund - Institutional Class (AFDZX)
$100,001 - $250,000
$1,001 - $2,500
4.3
American Funds Investment Co. of America - Class F-3 (FFICX)
$100,001 - $250,000
$5,001 - $15,000
4.4
American Funds New Perspective Fund - Class F-3 (FNPFX)
$15,001 - $50,000
$201 - $1,000
4.5
American Funds Fundamental Investors - Class F-3 (FUNFX)
$50,001 - $100,000
$2,501 - $5,000
4.6
American Funds Washington Mutual Investors Fund - Class F-3 (FWMIX)
$50,001 - $100,000
$5,001 - $15,000

Transactions

#
Description
Type
Date
Amount
Nothing reported in this section

Liabilities

#
Creditor
Amount
Incurred
Term
Nothing reported in this section

Gifts and Travel Reimbursements

#
Source Name
City
Description
Value
Nothing reported in this section

Endnotes

Section
#
Description
1
1
I have forgone compensation for my position at Bitterroot Bio, Inc.
1
4
I have forgone compensation for my position at Mayo Foundation for Medical Education & Research.
1
11
I have been employed by Duke University since 1980 when I was a clinical fellow, retiring in November 2019 and taking an adjunct professor position. The position renews annually.
1
12
I retired from Duke University in November 2019. However, my position as Donald F. Fortin, M.D. Distinguished Professor of Cardiology did not officially end until December 2019.
1
13
The Duke Center for Health Data Science was renamed as Duke Forge in October 2017.
1
21
My previous position title at Verily Life Sciences, LLC, was Head of Clinical Policy & Strategy until October 1, 2021. My duties for the company have not changed; only my position title changed. As part of my duties with the company, I lead the advisory board of Verily Life Sciences, LLC. I do not hold a separate position or title related to leading this advisory board, and I do not receive any additional compensation for it.
1
22
My previous position title at Google, LLC, was Head of Clinical Policy & Strategy for Google Health until October 1, 2021. My duties for the company have not changed; only my position title changed.
1
25
Subsequent to the submission of this report I resigned from this advisory board position and have not provided any services. I have not received any income for this advisory board position.
2
1
The advisory board fees that were payable by the Medical University of South Carolina to me were donated to charity on my behalf.
2
8
Upon my resignation from Centessa Pharmaceuticals, PLC, acceleration may be allowed for some stock options per company policy.

Do you have information about Robert Califf that is missing from this database?

Drop us a line at info@insidebidensbasement.org.

We want your help. If you have any additional information about an appointee that is or isn’t in our database, or any corrections, let us know via email at info@insidebidensbasement.org .

© 2022 Biden's Basement. All rights reserved